GLP-1 receptor agonists are having a moment
Given their widespread use and the frequency with which dermatology clinicians encounter patients taking GLP-1s, we felt it was important to characterize reported cutaneous adverse events at a population level
The proportion of patients completing these studies without the use of rescue medications was relatively high (77%, 62%, and 78% in PIONEER 2, 3, and 7, respectively
A review on bioavailability of magnesium and potassium salts noted that these minerals work synergistically in human nutrition (PMID: 40931546)
Endocrine Disorders in Kidney Disease , 127-138
(2.1) After 4 weeks, increase to 5 mg injected subcutaneously once weekly